Nelfinavir (AG 1343) Mesylate

For research use only.

Catalog No.S4282 Synonyms: Viracept

13 publications

Nelfinavir (AG 1343) Mesylate Chemical Structure

CAS No. 159989-65-8

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Selleck's Nelfinavir (AG 1343) Mesylate has been cited by 13 publications

Cell Rep, 2021, 35(10):109218

PubMed: 34038715 ( click the link to review the publication )

Protein Cell, 2021, 10.1007/s13238-021-00885-0

PubMed: 34677780 ( click the link to review the publication )

Sci Rep, 2021, 11(1):19443

PubMed: 34593846 ( click the link to review the publication )

World Scientific, 2021, Vol. 20, No. 03, pp. 305-322

PubMed: None ( click the link to review the publication )

Blood Adv, 2021, bloodadvances.2020003820

PubMed: 34649278 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, AAC.00872-20

PubMed: 32669265 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, AAC.01002-20

PubMed: 32601166 ( click the link to review the publication )

Leukemia, 2019, 33(1):37-51

PubMed: 29884901 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3757-3765

PubMed: 31262902 ( click the link to review the publication )

Immunity, 2018, 49(5):842-856

PubMed: 30366764 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):236

PubMed: 30241558 ( click the link to review the publication )

Pharm Res, 2011, 28(2):337-63

PubMed: 20945153 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HIV Protease Inhibitors

Biological Activity

Description

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Targets

HIV protease ^[1]
(Cell-free assay)

2 nM(Ki)

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HeLa	M3LhfGZ2dmO2aX;uJIF{e2G7			MV3UVH9VWkGQU2DPVnRGWjpiaX7obYJqfGmxbjDv[kBVTUFidYD0ZYtmKCiWRVG6JFExKHWPKTDpckBQS1RzLXX4dJJme3OrbnegTIVN[SClZXzsd{whUUN3ME2yNU45\|ryPLh?=	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB4OEGzO\|goRjFyNkixN\|c5RC:jPh?=
Caco-2	MXvGeY5kfGmxbjDhd5NigQ>?			M3LuVXRRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKESjdX7vdpVjcWOrbjD0doFve2WyaYTo[Yxq[WxidILhcpNxd3K2IDjiZZNidCC2bzDhdIlk[WxrIDjEZZVvd3K3YnnjbY47KDVidV2pJIlvKEOjY3:tNkBk\WyuczygTWM2OD1zLkVOwG0v	NWHvSVRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4NlAyOzdpPkGwPFIxOTN5PD;hQi=>
MT-4	MkDwRY51cX[rcnHsJIF{e2G7			MnOwRY51cS2KSW[tNUBi[3Srdnn0fUBi\2GrboP0JHdqdGRidInw[UB3cXK3czDpckBOXC12IHPlcIx{NCCHREWwQVAvODMQvF2u	M4\zZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNUSzOlc4Lz5zMUW0N\|Y4PzxxYU6=
MT-4	Ml7MRY51cX[rcnHsJIF{e2G7			M3XQbGFvfGlvSFnWMVEh[WO2aY\peJkh[WejaX7zeEBufXSjboSgTGlXNTFiaX6gUXQuPCClZXzsd{ApdXW2YYTpc44he2WuZXP0[YQhf2m2aDDjc41xd3WwZDCxLUwhTUR3ME2wMlA4\|ryPLh?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTV2M{[3O{c,OTF3NEO2O\|c9N2F-
MT-4	MmDKRY51cX[rcnHsJIF{e2G7			NWjqbI1TSW62aT3ITXYuOSCjY4Tpeol1gSCjZ3HpcpN1KG23dHHueEBJUVZvMTDpckBOXC12IHPlcIx{KCivdYTheIlwdiC\|ZXzlZ5Rm\CC5aYToJJJqfG:wYY\pdkktKEWGNUC9NE4yOc7:TT6=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTV2M{[3O{c,OTF3NEO2O\|c9N2F-
MT-4	MXzBcpRqfmm{YXygZZN{[Xl?			MWDBcpRqNUiLVj2xJIFkfGm4aYT5JIFo[Wmwc4SgcZV1[W62IFjJWk0yKGmwIF3UMVQh[2WubIOgLI12fGG2aX;uJJNmdGWldHXkJJdqfGhic3HxeYlv[X[rcjmsJGVFPTB;MD6xNu69VS5?	NGjqXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUW0N\|Y4Pyd-MUG1OFM3Pzd:L3G+
MT-4	NFLFPWpCdnSrdnnyZYwh[XO\|YYm=			M4Lob2FvfGlvSFnWMVEh[WO2aY\peJkh[WejaX7zeEBufXSjboSgTGlXNTFiaX6gUXQuPCClZXzsd{ApdXW2YYTpc44he2WuZXP0[YQhf2m2aDDu[YxncW6jdnnyLUwhTUR3ME2yMlQ1\|ryPLh?=	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3NEO2O\|coRjFzNUSzOlc4RC:jPh?=
LLC-PK1	NV3EOHNkTnWwY4Tpc44h[XO\|YYm=			NEHSNFVKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNCCvb4Xz[UBNNW2mckHhJIV5eHKnc4Pl[EBqdiCOTFOtVGsyKGWyaYTo[Yxq[WxiY3XscJMhfXOrbnegZ4Ft[2Wrbj3BUUBxd2yjcnnzZZRqd25iYYPzZZktKEmFNUC9Nk4{\|ryPLh?=	NWnpZnhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2PVk{QDlpPkGyOlk6Ozh7PD;hQi=>
LLC-PK1	NIjqVnhHfW6ldHnvckBie3OjeR?=			M3;hZXRRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKEOjbHPlbY4uSU1iZX\mcJV5KGmwIF3kdlFiNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whUUN3ME2yMlPPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ7OUO4PUc,OTJ4OUmzPFk9N2F-
LLC-PK1	NGP6c5JHfW6ldHnvckBie3OjeR?=			M3zheGlvcGmkaYTpc44hd2ZiUD3ncJlkd3C{b4TlbY4tKGi3bXHuJGwuVUSUMTDlfJBz\XO\|ZXSgbY4hVEyFLWDLNUBmeGm2aHXsbYFtKGOnbHzzJJV{cW6pIHPhcINmcW5vQV2gdI9t[XKrc3H0bY9vKGG\|c3H5MEBKSzVyPUOuOO69VS5?	NF:xeZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[5PVM5QSd-MUK2PVk{QDl:L3G+
LLC-PK1	M2rCXWZ2dmO2aX;uJIF{e2G7			NGLLU2JVWF:WUlHOV3BQWlSHUkqgbY5pcWKrdHnvckBw\iCFYXzj[YlvNUGPIHXm[ox2gCCrbjDNSHIyNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whUUN3ME2zMlTPxE1w	Mm[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4OUmzPFkoRjF{Nkm5N\|g6RC:jPh?=
HEK	MU\GeY5kfGmxbjDhd5NigQ>?			NX;EV5NTXFChVGLBUnNRV1KWRWK6JIlv[3KnYYPlJIlvKG2rdH;4ZY51em:wZTDpcpRz[WOnbHz1cIFzKGGlY4XteYxifGmxbjDpckBDS1KSLXX4dJJme3OrbnegTGVMKGOnbHzzMEBKSzVyPUGyMlXPxE1w	M3TQTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MEC3NVAzLz5zNUCwO\|ExOjxxYU6=
CEM-SS	MYXBcpRqfmm{YXygZZN{[Xl?		NFG5W483KGSjeYO=	MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFPFUU1UWyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYX\0[ZIhPiCmYYnzJIJ6KE2WUzDhd5NigSxiRVS1NF0xNjB\|zszNMi=>	NFjNW2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUKxO\|I5OSd-MUWyNVczQDF:L3G+
HOG.R5	NEfYb4hCdnSrdnnyZYwh[XO\|YYm=		M3jEelQh\GG7cx?=	MkLhRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDIU2cvWjViY3XscJMh[W[2ZYKgOEBl[Xm\|LDDJR\|UxRTBwMEpOwG0v	M1HvdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MkG3NlgyLz5zNUKxO\|I5OTxxYU6=
MT-4	NXLBNG1XTnWwY4Tpc44h[XO\|YYm=			NVf6UY5MTW[oZXP0bZZmKGSxc3Wgc4Yh[2:vcH;1coQhemWzdXny[YQhfG9iaX7obYJqfCC{ZYDsbYNifGmxbjDv[kBpfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KHS7cHWgNUBqdiCPVD20JINmdGy\|LDDFSFUxRTBwMENOwG0v	NUezTlVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1N\|c{PTBpPkG1OVM4OzVyPD;hQi=>
MT4	MVPBcpRqfmm{YXygZZN{[Xl?			MYrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEi[QkKgbY4hVVR2IHPlcIx{NCCLQ{WwQVAvOzMQvF2u	NGjBcmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS1PFUxPSd-MU[0OVg2ODV:L3G+
MT4	NV6xNXBbSW62aY\pdoFtKGG\|c3H5			NGLo[4FCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFXQNVMhcW5iTWS0JINmdGy\|LDDJR\|UxRTBwNEZOwG0v	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR3OEWwOUc,OTZ2NUi1NFU9N2F-
PHA-PBMC	M{DVd2FvfGm4aYLhcEBie3OjeR?=			NVn4ZZhPSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDCRU1NKGm\|b3zheIUhcW5iaIXtZY4hWEiDLWDCUWMh[2WubIOsJGlEPTB;MD6wNFfPxE1w	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjlzM{exOEc,OTZ7MUO3NVQ9N2F-
MT2	M4X4dmFvfGm4aYLhcEBie3OjeR?=			MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEyDSTDpd49t[XSnIHnuJIh2dWGwIF3UNkBk\WyuczygTWM2OD1yLkCx{txONg>?	M3nYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUGzO\|E1Lz5zNkmxN\|cyPDxxYU6=
PHA-PBMC	M2O5N2FvfGm4aYLhcEBie3OjeR?=			NYPLPHlZSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDMRWkhcXOxbHH0[UBqdiCqdX3hckBRUEFvUFLNR{Bk\WyuczygTWM2OD1yLkCxOO69VS5?	M{Gyd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUGzO\|E1Lz5zNkmxN\|cyPDxxYU6=
MT2	NG\OfmRCdnSrdnnyZYwh[XO\|YYm=			Mn[0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCHSF:gbZNwdGG2ZTDpckBpfW2jbjDNWFIh[2WubIOsJGlEPTB;MD6wNu69VS5?	MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NVQoRjF4OUGzO\|E1RC:jPh?=
PHA-PBMC	MnztRY51cX[rcnHsJIF{e2G7			NXX1[W9kSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhdXWudHmg[JJ2\y2{ZYPpd5RidnRiSFnWNUBGXCC4YYLpZY51KGmwIHj1cYFvKFCKQT3QRm1EKGOnbHzzMEBKSzVyPUCuNFMz\|ryPLh?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjlzM{exOEc,OTZ7MUO3NVQ9N2F-
PHA-PBMC	MkP3RY51cX[rcnHsJIF{e2G7			MmHzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgcZVtfGliZIL1[{1z\XOrc4ThcpQhUEmYMTDHJJZiemmjboSgbY4hcHWvYX6gVGhCNVCETVOgZ4VtdHNuIFnDOVA:OC5zN988UU4>	NVTBSWdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4OTRpPkG2PVE{PzF2PD;hQi=>
PHA-PBMC	MVXBcpRqfmm{YXygZZN{[Xl?			NETydWJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBufWy2aTDkdpVoNXKnc3nzeIFvfCCKSW[xJGMhfmG{aXHueEBqdiCqdX3hckBRUEFvUFLNR{Bk\WyuczygTWM2OD1yLkOx{txONg>?	NXjnd\|ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4OTRpPkG2PVE{PzF2PD;hQi=>
MT2	M3XhU2FvfGm4aYLhcEBie3OjeR?=			MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYzKEWKTzDpckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5yM988UU4>	M3fib\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT2	Ml3pRY51cX[rcnHsJIF{e2G7			MX\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEyDSTDpckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5yM{NOwG0v	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	M4jGfGFvfGm4aYLhcEBie3OjeR?=			MYDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIlvKE2WNDDj[YxteyCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wN\|PPxE1w	M3K1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NXXmT\|NLSW62aY\pdoFtKGG\|c3H5			NWTBe2tsSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDHVmw6QDB4NYCyNEBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wPO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MoDURY51cX[rcnHsJIF{e2G7			MULBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDybZRwdmG4aYKtdoV{cXO2YX70JGhKXjFiaX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gdFI1KEejZzDwdo91\WmwIHX4dJJme3Orb36gZpkhVVSWIHHzd4F6NCCHQ{WwQVAvOjIQvF2u	M1PrZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NXnTN2FPSW62aY\pdoFtKGG\|c3H5			MkDIRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgZY1xemWwYY\pdk1z\XOrc4ThcpQhUEmYMTDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5{Mt88UU4>	MorNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT2	MkOyRY51cX[rcnHsJIF{e2G7			MVnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYzKFKRRDDpckBOXDJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5{NN88UU4>	NX;Cd\|lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT4	MkTHRY51cX[rcnHsJIF{e2G7			NWrlUJFCSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qh[XSjenHuZZZqei2{ZYPpd5RidnRiSFnWNUBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yO:69VS5?	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	MWfBcpRqfmm{YXygZZN{[Xl?			NXPUbZFmSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDHVmw6QDB4NYCzNEBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yO:69VS5?	M4rOelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NYntOI97SW62aY\pdoFtKGG\|c3H5			Mk\TRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCJUly5PFA3PXB2MDDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5\|NN88UU4>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	NFfObW5CdnSrdnnyZYwh[XO\|YYm=			NWezXJlmSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhcWSrbnH2bZIuemW\|aYP0ZY51KEiLVkGgbY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJIV5eHKnc4Ppc44h[nliTWTUJIF{e2G7LDDFR\|UxRTBwNEhOwG0v	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	Mk\5RY51cX[rcnHsJIF{e2G7			MWDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDzZZF2cW6jdnnyMZJme2m\|dHHueEBJUVZzIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDlfJBz\XO\|aX;uJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjR6zszNMi=>	NH[wVYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O3NVgyOSd-MUezO\|E5OTF:L3G+
MT4	NHHxRZRCdnSrdnnyZYwh[XO\|YYm=			NVvRdo1LSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhdG:yaX7heolzNXKnc3nzeIFvfCCKSW[xJIlvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkS5{txONg>?	NVPt[o52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT2	NH;mblhEgXSxdH;4bYNqfHliYYPzZZk>			MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWFIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDwNlQhT2GpIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBOXFRiYYPzZZktKEOFNUC9PE4y\|ryPLh?=	M1v6N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NWm4fmVISW62aY\pdoFtKGG\|c3H5			NHjBeldCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlvKE2WNDDj[YxteyCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wNVbPxE1w	NY\Rb41GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1N\|c3OjhpPkG3OVM4PjJ6PD;hQi=>
MT4	Mkn3R5l1d3SxeHnjbZR6KGG\|c3H5			NXv1cIEyS3m2b4TvfIlkcXS7IHHnZYlve3RiTWS0JINmdGy\|IHL5JG1VXCCjc4PhfUwhVEN3ME2xNe69VS5?	NXnjPHN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1N\|c3OjhpPkG3OVM4PjJ6PD;hQi=>
MT4	MlfZRY51cX[rcnHsJIF{e2G7		NHHmU2U2KGSjeYO=	NVTvbodHSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZYZ1\XJiNTDkZZl{KGK7IF3UWEBie3OjeTygSWM2OD1yLkCxPO69VS5?	M3zFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PFQ5Lz5zN{W3Olg1QDxxYU6=
MT4	NEi4XYtCdnSrdnnyZYwh[XO\|YYm=		NUTyWlBEPSCmYYnz	M2D6SWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjJiTWOgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGGodHXyJFUh\GG7czDifUBOXFRiYYPzZZktKEWFNUC9NE4xPDkQvF2u	NFe0NFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W3Olg1QCd-MUe1O\|Y5PDh:L3G+
CEM	Mn\ORY51cX[rcnHsJIF{e2G7		NELtN\|g4KGSjeYO=	NWHlcGFxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2Qhf2m2aDDwdo91\WG\|ZTDHNVdPN1Z2N1GgcZV1[XSrb36gbY5n\WO2ZXSgbY4hcHWvYX6gR2VOKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNicILv[JVkfGmxbjDh[pRmeiB5IHThfZMh[nliTHXueIkuWlRiYXP0bZZqfHliYYPzZZktKEWFNUC9NE4y\|ryPLh?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5Nki0PEc,OTd3N{[4OFg9N2F-
CEM	MlrSRY51cX[rcnHsJIF{e2G7		M1nxTVch\GG7cx?=	M1vFNWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjJiUl;EJJdqfGhicILveIVie2ViVkS3RUBufXSjdHnvckBqdm[nY4Tl[EBqdiCqdX3hckBETU1iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3czDwdo9lfWO2aX;uJIFnfGW{IEeg[IF6eyCkeTDM[Y51cS2UVDDhZ5Rqfmm2eTDhd5NigSxiRVO1NF0xNjF5N988UU4>	M2HPb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PFQ5Lz5zN{W3Olg1QDxxYU6=
CEM	MUfBcpRqfmm{YXygZZN{[Xl?		MmPaO{Bl[Xm\|	NYPNe2ZXSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2Qhf2m2aDDwdo91\WG\|ZTDHNVdPKG23dHH0bY9vKGmwZnXjeIVlKGmwIHj1cYFvKEOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzJJBzd2S3Y4Tpc44h[W[2ZYKgO{Bl[Xm\|IHL5JGxmdnSrLWLUJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwMUm5{txONg>?	NWPE[G1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	M1vhTGFvfGm4aYLhcEBie3OjeR?=		MV63JIRigXN?	NGXBb\|VCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMjDSU2QhcW6oZXP0[YQhcW5iaIXtZY4hS0WPIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOgdJJw\HWldHnvckBi\nSncjC3JIRigXNiYomgUIVvfGlvUmSgZYN1cX[rdImgZZN{[XluIFXDOVA:OC5{OEJOwG0v	Mn;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[4OFgoRjF5NUe2PFQ5RC:jPh?=
HEK293	NVfvUnY6SW62aY\pdoFtKGG\|c3H5		M3jRT\|Q5KGi{cx?=	MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgTGlXOSCQTEStN{BqdiCKRVuyPVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IILldIxq[2G2aX;uMYRm\m[nY4TpeoUhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lMYJie2WmIIDo[Y5wfHmyaXOgZZN{[XluIFXDOVA:OC5yMEW4{txONg>?	NVjB[5hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N\|g3QTRpPkG3OlM5Pjl2PD;hQi=>
MT4	M3P1TWFvfGm4aYLhcEBie3OjeR?=		NHTITGY3KGSjeYO=	NIXvenFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTDOUFQuOyCrbn\lZ5Rm\CCrbjDNWFQh[2WubIOgZYZ1\XJiNjDkZZl{KGK7IF3UWEBie3OjeTygSWM2OD1yLkCyPe69VS5?	M3zBfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkO4Olk1Lz5zN{[zPFY6PDxxYU6=
MT4	NIrzTHREgXSxdH;4bYNqfHliYYPzZZk>		Mmj6OkBl[Xm\|	NIPpboZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXDRiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhS0N3ME24{txONg>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ\|OE[5OEc,OTd4M{i2PVQ9N2F-
HEK293	Mnf3SpVv[3Srb36gZZN{[Xl?	MXWwMlEzKHWP		Mn[1TY5pcWKrdHnvckBw\iCKSW[xJG5NPC1\|IIDyc5RmcW6\|IHnuZ49zeG:{YYTpc44hcW62bzD2bZJqd26\|IITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{B2dnC{b3Pld5Nm\CCpcEG2NEBGdnZicILveIVqdiCjdDCwMlEzKHWPIHL5JHdme3Sncn6gZoxwfA>?	MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NE[0NVAoRjF5NkS2OFExRC:jPh?=
HEK293	MWrGeY5kfGmxbjDhd5NigQ>?	MorONE4yOiC3TR?=		NUn1dGhLUW6qaXLpeIlwdiCxZjDITXYyKE6OND2zJJBzd3SnaX7zJIlv[2:{cH;yZZRqd25iaX70c{B3cXKrb37zJJRz[W6\|ZnXjeIVlKGmwIFjFT\|I6OyClZXzsd{Bie3Onc4Pl[EBieyCjYnXydoFvfCCHbo[gdJJwfGWrbjDheEAxNjF{IIXNJIJ6KFenc4Tldo4h[myxdB?=	MnfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NE[0NVAoRjF5NkS2OFExRC:jPh?=
MDCK2	MXfJcohq[mm2aX;uJI9nKGi3bXHu			M4i2UmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSUMT3k[ZBmdmSnboSgZYNkfW23bHH0bY9vKG:oIHPhcINmcW5vQV2g[ZhxemW\|c3XkJIlvKE2GQ1uyJINmdGy\|LDDJR\|UxRTF7LkpOwG0v	M3jOTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[0N\|I4Lz5zN{[2OFMzPzxxYU6=
MDR1	NXnF[4JTTnWwY4Tpc44h[XO\|YYm=	Moi2NlAhfU1?		M2m0emRm[3KnYYPlJIlvKFBvZ3z5Z49xem:2ZXnuMY1m\GmjdHXkJJRmdm:ob4\pdkBlcXOxcILvfIltKG[3bXHyZZRmKGWoZnz1fEBqdiCPRFPLNkBmgHC{ZYPzbY5oKGi3bXHuJG1FWjFiY3XscJMh[XRiMkCgeW0>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4NEOyO{c,OTd4NkSzNlc9N2F-
CEM-SS	NXW2XFlFSW62aY\pdoFtKGG\|c3H5		M4rBTlUh\GG7cx?=	NHrVNpBCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFzBTUBqdm[nY4Tl[EBqdiCqdX3hckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoV3\XK\|ZTD0doFve2O{aYD0ZZNmKGGldHn2bZR6KGGodHXyJFUh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODMQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl3MEm1OUc,OTd7NUC5OVU9N2F-
MOLT-4/3B	MWfBcpRqfmm{YXygZZN{[Xl?		NUPpcIpLPCCmYYnz	NX3GdW9WSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCPT1zUMVQwO0JiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBu[XS3cnWgeolzfXNicnXs[YF{\SCvZXHzeZJm\CCjZoTldkA1KGSjeYOgc4YhcW6oZXP0bY9vKGK7IGLUJIF{e2G7LDDFR\|UxRTBwMEK5{txONg>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzNkWyNUc,OTh\|MU[1NlE9N2F-
MT4	MVvBcpRqfmm{YXygZZN{[Xl?			M3q0TGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQhdWW2aH;kMEBGSzVyPUCuNFE3\|ryPLh?=	NUTuSWR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlYyQTVpPkG4OFI3OTl3PD;hQi=>
MT4	M1nvZWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MljYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIJ6KE2WVDDhd5NigSxiQ1O1NF0yOc7:TT6=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NkG5OUc,OTh2Mk[xPVU9N2F-
MT4	NEHqeI9CdnSrcnX0do93cXKjbDDhd5NigQ>?			MYrBcpRqemW2cn;2bZJidCCjY4Tpeol1gSCjZ3HpcpN1KEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjB{M988UU4>	NIriVnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT4	MWHBcpRqemW2cn;2bZJidCCjc4PhfS=>			MVPBcpRqemW2cn;2bZJidCCjY4Tpeol1gSCjZ3HpcpN1KEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlAzQM7:TT6=	MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	NIX1NpNCdnSrdnnyZYwh[XO\|YYm=			NHfXfmJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBT\X[ncoPlJJRz[W6\|Y4LpdJRie2ViaX7obYJqfG:{LYLld4l{fGGwdDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUC9NE4xOjoQvF2u	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	MofvRY51cX[rcnHsJIF{e2G7			MWjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDuc44hdnWlbHXvd4ll\SC{ZY\ldpNmKHS{YX7zZ5JqeHSjc3WgbY5pcWKrdH;yMZJme2m\|dHHueEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBjgSCPVGSgZZN{[XluIFXDOVA:OC5yM{ZOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	NUDnNWVkSW62aYLleJJwfmm{YXygZZN{[Xl?			M{ji[WFvfGm{ZYTyc5ZqemGuIHHjeIl3cXS7IHHnZYlve3RiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCyJGVJVyCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjB2Od88UU4>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	MYnBcpRqemW2cn;2bZJidCCjc4PhfS=>			NYnjRohzSW62aYLleJJwfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFIhWk:GIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEZOwG0v	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	M3KwZmFvfGm{ZYTyc5ZqemGuIHHzd4F6			Mk\5RY51cXKndILveolz[WxiYXP0bZZqfHliYXfhbY5{fCCVaX3pZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czDNRWMhOjVzIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEZOwG0v	MkWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	M3nZeWFvfGm4aYLhcEBie3OjeR?=			MYLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDQdo91\WG\|ZTDpcohq[mm2b4KtdoV{cXO2YX70JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjF5zszNMi=>	NHrC[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT4	MWHBcpRqfmm{YXygZZN{[Xl?	NYnrbIRrPSC3TR?=		M4W1PGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcGG{Yn;ybY5oKExzMF[vUFM{Ti:PNE\JM2k1P1ZxUUW4SU9XQDKLL1m4OHYwUTh3VjDhcYlvdyCjY3nkJJN2[nO2aYT1eIlwdiCrbjDwdo91\WG\|ZTDlcoNw\GmwZzDy[Ydqd25iaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicEK0JGdi\yCycn;0[YlvKHC{b3T1Z5Rqd25ic3Xs[YN1\WRiYYSgOUB2VSCxZjDHVmwuODJyM{GgZpkhTSxiRVO1NF0xNjBzMd88UU4>	NFO3bGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
MT4	NI\DZ41CdnSrdnnyZYwh[XO\|YYm=			MVrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCpYXegdJJwfGWrbjDwdo9lfWO2aX;uJIJ6KEWOSWPBMEBGSzVyPUCuNFE5\|ryPLh?=	M4D4c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT2	NHvVUI1CdnSrdnnyZYwh[XO\|YYm=		M1nLOlch\GG7cx?=	NYjpeVNsSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDMRWkhcW6oZXP0[YQhcW5iaIXtZY4hVVR{IHPlcIx{KGGodHXyJFch\GG7czDifUBOXFRiYYPzZZktKEWFNUC9NE4xOjQQvF2u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3NUWxPEc,OTh7NUW1NVg9N2F-
MT4	NYT1e2JqSW62aY\pdoFtKGG\|c3H5	Ml\tOUB2VQ>?		MnPIRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDFyRj;WN\|JKN012NlmvTVU1VS9xQUexWk9KQDSYIHHtbY5wKGGlaXSgd5Vje3SrdIX0bY9vKGmwIIDyc5Rm[XOnIHXuZ49lcW6pIILl[4lwdiCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4heHKxZIXjeIlwdiC\|ZXzlZ5Rm\CCjdDC1JJVOKG:oIHHtdJJmdmG4aYKgZpkhTUyLU1GsJGVEPTB;MD6xO:69VS5?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3NUWxPEc,OTh7NUW1NVg9N2F-
MT4	NH7DeFNCdnSrdnnyZYwh[XO\|YYm=	M3HQRVEhfU1?		NXvhbGZISW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCqYYLic5JqdmdiTEKzTU9MPDOLL120OmkwUTVyTD;HOVFCN0F5MW[gZY1qdm9iYXPp[EB{fWK\|dHn0eZRqd25iaX6gdJJwfGWjc3Wg[Y5kd2SrbnegdoVocW:wIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIICyOEBI[WdicILveIVqdiCycn;keYN1cW:wIIPlcIVkfGWmIHH0JFEhfU1ib3[gZZRigmGwYY\pdkBjgSCHTFnTRUwhTUN3ME2wMlIy\|ryPLh?=	Mn3EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	MkPGRY51cX[rcnHsJIF{e2G7	MX21JJVO		Mk\XRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVTR4ST;WPFJHN0l6NG[gZY1qdm9iYXPp[EB{fWK\|dHn0eZRqd25iaX6gdJJwfGWjc3Wg[Y5kd2SrbnegdoVocW:wIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIICyOEBI[WdicILveIVqdiCycn;keYN1cW:wIIPlcIVkfGWmIHH0JFUhfU1ib3[gdol1d26jdnnyJIJ6KEWOSWPBMEBGSzVyPUCuNlTPxE1w	NF;zWZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
MT4	M2fRWWFvfGm4aYLhcEBie3OjeR?=	NX7VfYpiPSC3TR?=		M4C0SmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcGG{Yn;ybY5oKExzMFmvS\|Q5Xi:LNUTWM2w6OE1iYX3pco8h[WOrZDDzeYJ{fGm2dYTpc44hcW5icILveIVie2ViZX7jc4RqdmdicnXnbY9vKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBxem:mdXP0bY9vKHOnbHXjeIVlKGG2IEWgeW0hd2Zic3HxeYlv[X[rcjDifUBGVEmVQTygSWM2OD1yLkOy{txONg>?	MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	NW\lWJdOSW62aY\pdoFtKGG\|c3H5	M4LYT\|EhfU1?		MV;BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIhiemKxcnnu[{BNOTCIL120OmkwUTV2Vj;WPFJCKGGvaX7vJIFkcWRic4Xid5RqfHW2aX;uJIlvKHC{b4TlZZNmKGWwY3;kbY5oKHKnZ3nvckBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6gdJJw\HWldHnvckB{\WynY4Tl[EBifCBzIIXNJI9nKEyxcHnuZZZqeiCkeTDFUGlUSSxiRVO1NF0xNjVzzszNMi=>	Ml;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	NXu4TWd7SW62aY\pdoFtKGG\|c3H5	M2HTdFUhfU1?		NFz2NHRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGijcnLvdolv\yCOMUDGM2wzPElxTUS2TU9NPjOSL1G3NXYwTzd\|Uz;WPFJVKGGvaX7vJIFkcWRic4Xid5RqfHW2aX;uJIlvKHC{b4TlZZNmKGWwY3;kbY5oKHKnZ3nvckBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6gdJJw\HWldHnvckB{\WynY4Tl[EBifCB3IIXNJI9nKGmwZHnuZZZqeiCkeTDFUGlUSSxiRVO1NF0xNjZ3zszNMi=>	NH7CVHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
HeLa	MljlRY51cX[rcnHsJIF{e2G7		M4nsXVczKGi{cx?=	MkjkRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCqYYLic5JqdmdiY3Hwd4llKEl{MEHWJI12fGGwdDDwdo91\WmwIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5idnnyZYwhcW6oZXP0bY9vKGGodHXyJFczKGi{czDifUBj\XSjLXfhcIFkfG:\|aXThd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzM988UU4>	NUDiZlBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFU2PzFpPkG5PFA2PTdzPD;hQi=>
HeLa	NWfjR242SW62aY\pdoFtKGG\|c3H5		MlTtO\|IhcHK\|	MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgTGlXOSCrbn\lZ5Rm\CCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKH[rcnHsJIlv\mWldHnvckBi\nSncjC3NkBpenNiYomgZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xOTcQvF2u	Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MEW1O\|EoRjF7OEC1OVcyRC:jPh?=
HeLa	M{LTZ2FvfGm4aYLhcEBie3OjeR?=		MmfKO\|IhcHK\|	MknGRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCqYYLic5Jqdmdic4DhZ4VzKHCncITp[IUhSTGYIH31eIFvfCCycn;0[YlvKGmwZnXjeIVlKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hfmm{YXygbY5n\WO2aX;uJIFnfGW{IEeyJIhzeyCkeTDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA{QM7:TT6=	M3XhfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEC1OVcyLz5zOUiwOVU4OTxxYU6=
cord blood mononuclear cells	Ml7GRY51cX[rcnHsJIF{e2G7		Mnv0OFghcHK\|	MknYRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFic4XieJlx\SCFIHnu[oVkfGWmIHnuJIh2dWGwIHPvdoQh[myxb3SgcY9vd263Y3zlZZIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuNFAyPjgQvF2u	NGD1VWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
cord blood mononuclear cells	MXHBcpRqfmm{YXygZZN{[Xl?		M3ywXlQ5KGi{cx?=	MkjERY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFic4XieJlx\SCFUl[wNn9CTyCrbn\lZ5Rm\CCrbjDoeY1idiClb4LkJIJtd2:mIH3vco9vfWOuZXHyJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkCwOVfPxE1w	M{LodlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
cord blood mononuclear cells	MVrBcpRqfmm{YXygZZN{[Xl?		MXq0PEBpenN?	NUXjSlBRSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEiLVkGgd5VjfHmyZTDCJIlv\mWldHXkJIlvKGi3bXHuJINwemRiYnzvc4QhdW:wb371Z4xm[XJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODB7ON88UU4>	M{njRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
cord blood mononuclear cells	Mn3NRY51cX[rcnHsJIF{e2G7		NGXafoo1QCCqcoO=	MWLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhS1KIMELfRWchcGG{Yn;ybY5oKHC{b4TlZZNmKHCxbIntc5JxcGm\|bTDheEBKOzZicH;zbZRqd25iYX7kJG01PiCvdYThcpQh\2WwZTDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA2Pc7:TT6=	NUT0codGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	NGSwZXJCdnSrdnnyZYwh[XO\|YYm=		M4n5flQ5KGi{cx?=	MXnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhS1KIMELfRWchcGG{Yn;ybY5oKHC{b4TlZZNmKEx\|M1msJG01PkluIFG3NXQhdXW2YX70JIdmdmViYX7kJJBwdHmvb4LwbIl{dSCjdDDNN\|YheG:\|aYTpc44hcW6oZXP0[YQhcW5iaIXtZY4h[2:{ZDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIUtKEWFNUC9NE4zODMQvF2u	NFi1doU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
cord blood mononuclear cells	NYjINWFESW62aY\pdoFtKGG\|c3H5		NYK2dYRTPDhiaILz	MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSyCqYYLic5JqdmdicILveIVie2ViTEKzTUwhVTR4STygUFg6XCCvdYThcpQh\2WwZTDhcoQheG:ueX3vdpBpcXOvIHH0JG0{PiCyb4PpeIlwdiCrbn\lZ5Rm\CCrbjDoeY1idiClb4LkJIJtd2:mIH3vco9vfWOuZXHyJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UAtKEWFNUC9NE4zPzMQvF2u	NHe1RoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
cord blood mononuclear cells	MmLJRY51cX[rcnHsJIF{e2G7		M1vkU\|Q5KGi{cx?=	NYLGZ2VWSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDzeYJ1gXCnIFKgbIFz[m:{aX7nJJBzd3SnYYPlJGQ{OE5uIF20OmktKEF5MWSgZY5lKFZ5N1mgcZV1[W62IHflcoUh[W6mIIDvcJlud3KyaHnzcUBifCCPM{[gdI9{cXSrb36gc4YheHKxdHXhd4UhcW6oZXP0[YQhcW5iaIXtZY4h[2:{ZDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFQ5KGi{czDifUBtfWOrLDDFR\|UxRTFwMUO5{txONg>?	NUPYdJVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	MljIRY51cX[rcnHsJIF{e2G7		MknkOFghcHK\|	MmG4RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC\|dXL0fZBmKEJiaHHyZo9zcW6pIIDyc5Rm[XOnIFSzNG4tKEx\|M1msJG01PkluIF64PGQhdXW2YX70JIdmdmViYX7kJJBwdHmvb4LwbIl{dSCjdDDJN\|YheG:\|aYTpc44hcW6oZXP0[YQhcW5iaIXtZY4h[2:{ZDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzNCCHQ{WwQVEvPDZ\|zszNMi=>	NXnaNINvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	NHrtU21CdnSrdnnyZYwh[XO\|YYm=		MojOOFghcHK\|	NWLa[nZHSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDzeYJ1gXCnIFOgbIFz[m:{aX7nJJBzd3SnYYPlJGQ{OE5uIFWzOWctKEl6NW[sJGw6OE1ibYX0ZY51KGenbnWgZY5lKHCxbIntc5JxcGm\|bTDheEBKOzZicH;zbZRqd25iaX7m[YN1\WRiaX6gbJVu[W5iY3;y[EBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{LDDFR\|UxRTNwNEez{txONg>?	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
TZM-bl	M2C5XWFvfGm4aYLhcEBie3OjeR?=		M1Lvd\|Q5KGi{cx?=	MYPBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSiCqYYLic5JqdmdicILveIVie2VicH;sfY1wenCqaYPtJIF1KE1\|NjDwc5NqfGmxbjDpcoZm[3SnZDDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	NXG4dYVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
TZM-bl	M{jsfWFvfGm4aYLhcEBie3OjeR?=		MXG0PEBpenN?	MYLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhS1KIMELfRWchcGG{Yn;ybY5oKHC{b4TlZZNmKHCxbIntc5JxcGm\|bTDheEBKOzZicH;zbZRqd25iaX7m[YN1\WRiaX6gbJVu[W5iVGrNMYJtKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
TZM-bl	MXLBcpRqfmm{YXygZZN{[Xl?		NHG0V3k1QCCqcoO=	MUXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSiCqYYLic5JqdmdicILveIVie2VicH;sfY1wenCqaYPtJIF1KEl\|NjDwc5NqfGmxbjDpcoZm[3SnZDDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	NIC2R3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOFEzOyd-MkC0NFQyOjN:L3G+
MT4	NFmwNHFCdnSrdnnyZYwh[XO\|YYm=			MoX3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OD1yLkC0Oe69VS5?	MkfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	NX3jRWJQSW62aY\pdoFtKGG\|c3H5			MVXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwTU9NOjSLL120OmkwXjh{ST;JPFRXKG23dHHueEBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMhe2WuZXP0[YQh[W[2ZYKgOVAheGG\|c3Hn[ZMhd2ZiR2LMMVIyPiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6xN:69VS5?	NVXhT3hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	NWHNO4c4SW62aY\pdoFtKGG\|c3H5	NH\ZdJUyKHWP		MWfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwSk9OPD[PLFmvVVYyWSCvdYThcpQhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KHOnbHXjeIVlKGG2IEGgeW0hd2ZiR2LMMVM6PiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yNu69VS5?	M2Dye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO5OlEzLz5{MESzPVYyOjxxYU6=
MT4	NWTaeIRbSW62aY\pdoFtKGG\|c3H5	MknrNUB2VQ>?		NGPFS29CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\JM3Q6OVNibYX0ZY51KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyC\|ZXzlZ5Rm\CCjdDCxJJVOKG:oIFfSUE0zPDZiYomgUXRVKGG\|c3H5MEBGSzVyPUCuNlnPxE1w	NXKwVFluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	M33LTWFvfGm4aYLhcEBie3OjeR?=	MYW1JJVO		NH35Oo9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\JM2k2OFZxQUexWk9KQDSYL1y5NG0hdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{B{\WynY4Tl[EBifCB3IIXNJI9nKGGvcILlcoF3cXJiYomgUXRVKGG\|c3H5MEBGSzVyPUCuN:69VS5?	NEDjR4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzPVYyOid-MkC0N\|k3OTJ:L3G+
MT4	NH;wfXhCdnSrdnnyZYwh[XO\|YYm=	M4rUTFUhfU1?		NXWyPWtJSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDlfJBz\XO\|aX7nJJBzd3SnYYPlJGwyOEZxTUS2TU9KPTSYL2[4NmEhdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{B{\WynY4Tl[EBifCB3IIXNJI9nKEyxcHnuZZZqeiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6zNu69VS5?	NV7ERnJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	MVHBcpRqfmm{YXygZZN{[Xl?	NIe1RWwyKHWP		NF\iSIZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\MM2k2OFZxQUexWo12fGGwdDDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgd4Vt\WO2ZXSgZZQhOSC3TTDv[kBIWkxvMki2JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjN5zszNMi=>	NIP3S3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzPVYyOid-MkC0N\|k3OTJ:L3G+
MT4	MkDuRY51cX[rcnHsJIF{e2G7	MkDpOUB2VQ>?		MmjIRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCneIDy[ZN{cW6pIIDyc5Rm[XOnIFyxNGkwTzR6Vj;JOVRXN0F5MW[vTVg1Xi:OOUDNJI12fGGwdDDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgd4Vt\WO2ZXSgZZQhPSC3TTDv[kB{[XG3aX7heolzKGK7IF3UWEBie3OjeTygSWM2OD1yLkWx{txONg>?	M2rGOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO5OlEzLz5{MESzPVYyOjxxYU6=
BESM	M4SwVWFvfGm2conwZY5we2:vYXygZZN{[Xl?		NVG4NlFlQDhiaILz	MkD3RY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTDh[4FqdnO2IGTyfZBidm:\|b33hJINzfXqrIHHtZZN1cWexdHXzJIlv\mWldHXkJIlvKEKHU12gZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhQDhiaILzJJBwe3Srbn\lZ5Rqd25iYomgTHRUKGG\|c3H5MEBGSzVyPUGy{txONg>?	M3vVV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUS3PFE6Lz5{MEW0O\|gyQTxxYU6=
BESM	NHHZcXJEgXSxdH;4bYNqfHliYYPzZZk>		MXO4PEBpenN?	NVv2OXpIS3m2b4TvfIlkcXS7IHHnZYlve3RiQlXTUUBk\WyuczDh[pRmeiB6ODDodpMh[nliSGTTJIF{e2G7LDDFR\|UxRTN{zszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV2N{ixPUc,OjB3NEe4NVk9N2F-
CMEC/D3	NHjBOmZHfW6ldHnvckBie3OjeR?=		Mk\vN\|AhdWmwcx?=	M{S5b2lvcGmkaYTpc44hd2ZiUD3ndEBqdiCqdX3hckBEVUWFL1SzJINmdGy\|IIXzbY5oKE6ERD3BZoEh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVEvP87:TT6=	Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
CMEC/D3	M4ntSWZ2dmO2aX;uJIF{e2G7		NEDQXoc{OCCvaX7z	Ml24TY5pcWKrdHnvckBw\iCSLXfwJIlvKGi3bXHuJGNOTUNxREOgZ4VtdHNidYPpcoch[2GuY3Xpck1CVSCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Os7:TT6=	M{Lv[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUC1PVI5Lz5\|MUWwOVkzQDxxYU6=
12D7-MDR	MmO1SpVv[3Srb36gZZN{[Xl?		MX:zNEBucW6\|	NV6xNY1FUW6qaXLpeIlwdiCxZjDQMYdxKGmwIHj1cYFvKDF{REetUWRTKGOnbHzzJJV{cW6pIF7CSE1C[mFiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTVwON88UU4>	NG\LNVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUWwOVkzQCd-M{G1NFU6Ojh:L3G+
12D7-MDR	M1\wNmZ2dmO2aX;uJIF{e2G7		NFe3TWg{OCCvaX7z	NF;oSHNKdmirYnn0bY9vKG:oIGCt[5AhcW5iaIXtZY4hOTKGNz3NSHIh[2WubIOgeZNqdmdiY3HsZ4Vqdi2DTTDhd{B{fWK\|dILheIUh[W[2ZYKgN\|AhdWmwczDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYOsJGlEPTB;OT6x{txONg>?	MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
12D7	M3z5cmFvfGm4aYLhcEBie3OjeR?=		MYCzJIRigXN?	MlzmRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCOQVmgbY5n\WO2ZXSgbY4hcHWvYX6gNVJFPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDwMYdxKGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBROjRibHX2[Ywh[XRiMUqxJJJifGmxIH;mJJRme3RiY3;tdI92dmRidH:gZYJi[2G4aYKgbY5kfWKjdHXkJIZweiB\|IHThfZMh\m:ubH;3[YQh[nliZn;scI94\WRiYomgdoVxdGGlZX3lcpQhd2ZiZoLld4ghdWWmaYXtJINwdnSjaX7pcoch[2:vcH;1coQ>	M2e2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUC1PVI5Lz5\|MUWwOVkzQDxxYU6=
12D7	MXfBcpRqfmm{YXygZZN{[Xl?	NGjX[JExNjB6IITvJFEvOjVidV2=	NYLHblRTOyCmYYnz	MWrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEyDSTDpcoZm[3SnZDDpckBpfW2jbjCxNmQ4KGOnbHzzJI93\XKneIDy[ZN{cW6pIICt[5Ah[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHAzPCCuZY\lcEBifCByLkC4JJRwKDFwMkWgeW0hcW6ldXLheIVlKG[xcjCzJIRigXNiZn;scI94\WRiYomgdoVxdGGlZX3lcpQhd2ZiZoLld4ghdWWmaYXtJINwdnSjaX7pcoch[2:vcH;1coQh[W6mIH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCHTFnTRS=>	NWnlRZNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1NFU6OjhpPkOxOVA2QTJ6PD;hQi=>
SJ-GBM2	NWPhfFlVeUiWUzDhd5NigQ>?			NUD1fVdmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	M3LIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NIfSU5hyUFSVIHHzd4F6			M1PqWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	MoX6dWhVWyCjc4PhfS=>			MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NUCybW9MeUiWUzDhd5NigQ>?			NHnhWldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M3\ob\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NFe2SW9yUFSVIHHzd4F6			MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NHnvfnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	M37zUpFJXFNiYYPzZZk>			MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MoW2dWhVWyCjc4PhfS=>			M2Dve5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NIHG[Fk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MT2	NVnCVYFLSW62aY\pdoFtKGG\|c3H5		M4qxe\|Uh\GG7cx?=	MlW0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIF{e2W\|c3XkJIF{KH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZYZ1\XJiNTDkZZl{KGK7IGjUWEBie3OjeTygSWM2OD1yLkCwOFnPxE1w	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1PFQwLz6FaFXNRmw9N2F-
HepG2	M3[xUGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NY\EeJBrPSCmYYnz	MmXCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSC[VGSgZZN{[XluIFPDOVA:Py52zszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1PFQwLz6FaFXNRmw9N2F-
skeletal myoblast cells	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=		MUW3NkBpd3W{cx?=	MkXaSG5FUTpiQ4n0c5RwgGmlaYT5JIlvKF[rdILvMEA4OiCqb4XyMEBqdiC{YYSgd4tmdGW2YXygcZlw[myjc4SgZ4VtdHNuIFnDOVA:OTJwMEZOwG0v	NY\Ne4d2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTh2Lze+R4hGVUKOPD;hQi=>
MT2	MlKyR5l1d3SxeHnjbZR6KGG\|c3H5		MnrlOUBl[Xm\|	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWFIh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFUh\GG7czDifUBZXFRiYYPzZZktKEOFNUC9NVkvOc7:TT6=	MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVg1Nyd-Q3jFUWJNRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Growth inhibition assay	Cell viability; PubMed: 22271897 Haematologica Histograms show the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines treated with nelfinavir (1 μM to 10 μM).	22271897
Western blot	p-eIF2Aα / eIF2Aα / ATF4 / GRP78 / CHOP ; PubMed: 21697087 J Biol Chem U251 cells were mock-treated (0) or treated with Nelfinavir (NFV) (20 μm) for 4 or 24 h then whole cell lysates were immunoblotted for P-eIF2α, eIF2α, ATF4, GRP78, CHOP, and Ran, as indicated. SOD1 / SOD2 / catalase ; PubMed: 27280849 PLoS One Protein lysates derived from MDA-MB231, MCF-7, or breast epithelial cells, treated with 10 μM nelfinavir for the indicated time points, were immunoblotted with anti- SOD1, anti-SOD2 and anti-catalase. Beta-actin was used as loading control. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Western blot of the indicated cell lines treated with 10 μM nelfinavir for 24 hr for PAX3, MITF, and ERK2.	21697087 27280849 26977879
Immunofluorescence	LC3 / p62 ; PubMed: 27330277 Drug Des Devel Ther Immunofluorescence of cells treated with control 0.1% dimethyl sulfoxide or 10 μM nelfinavir for 24 hours. Scale bars indicate 10 μm and apply to all images. Punctate LC3 were quantified as autophagosomes and punctate p62 were quantified as sequestosomes, P<0.01, *P<0.001. (C and D) Western blot of lysates prepared following 24 hours of drug treatment. Nelfinavir was used at 10 μM and the autophagy clearance inhibitor chloroquine at 10 μM. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for PAX3 and MITF in WM266-4 cells left untreated or treated with 10 μM nelfinavir for 24 hr; scale bars, 50 μm. p-SMAD2 ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for phospho-SMAD2 in melanoma cells treated with nelfinavir; scale bars, 10 μm	27330277 26977879

In vivo

In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. Initial investigation of the compound in fed rats indicated an oral bioavailability of 43%. In contrast, the oral bioavailability was significantly reduced in fasted rats to 29%. Nelfinavir demonstrated significant oral bioavailabilability across a range of species including dogs (47%), marmosets (17%), and cynomolgus monkeys (26%). It has a long plasma half-life after oral dosing that is likely due to a combination of slow dissolution and absorption. nelfinavir is well absorbed in humans particularly when administered with food and possesses minimal and easily managed side effects^[1].

Protocol

Animal Research: ^[1]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 12.5 to 25 mg/kg (i.v); 25 to 50 mg/kg (oral) Administration: i.v and oral administration (Only for Reference)

References

[1] Kaldor SW, et al.J Med Chem, 1997,40(24):3979-85.

Solubility (25°C)

In vitro	DMSO	100 mg/mL (150.62 mM)
	Water	Insoluble
	Ethanol	''100 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Nelfinavir (AG 1343) Mesylate SDF

Molecular Weight	663.89
Formula	C₃₃H₄₉N₃O₇S₂
CAS No.	159989-65-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Viracept
Smiles	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HIV Protease Signaling Pathway Map

Related HIV Protease Products

Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
Ledipasvir (GS5885) ^New

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Ritonavir (ABT-538)

Ritonavir (ABT-538, A 84538, RTV, Norvir, Norvir Softgel) is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis.
Lopinavir (ABT-378)

Lopinavir (ABT-378) is a potent HIV protease inhibitor with K_i of 1.3 pM in a cell-free assay.
Darunavir Ethanolate

Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
Amprenavir (VX-478)

Amprenavir (VX-478, 141W94, KVX-478) is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV.
Atazanavir (BMS-232632) Sulfate

Atazanavir Sulfate (BMS-232632) is a HIV protease inhibitor with K_i of 2.66 nM in a cell-free assay.

Features:Atazanavir is generally more potent than other HIV-1 Prt inhibitors, including IDV, SQV, RTV, NFV, and APV.
MG-132

MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Nelfinavir (AG 1343) Mesylate